Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Epilepsy · Attention-Deficit/Hyperactivity Disorder (ADHD) · SUPN

SUPERNUS PHARMACEUTICALS

SUPERNUS PHARMACEUTICALS, INC.

SUPERNUS PHARMACEUTICALS patent portfolio — 68 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
9715 Key West Ave, Rockville, Maryland 20850, US HQ
2005 Founded
828 Employees
Public company Type
SUPN · NYSE Ticker
Company details
Status
Public
HQ
9715 Key West Ave, Rockville, Maryland 20850, US
Founded
2005
Employees
828
Programs
55
Drugs
25
Patents
68
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

SUPERNUS PHARMACEUTICALS patents

68 pharmaceutical patents indexed for SUPERNUS PHARMACEUTICALS. 1 expire within 24 months.

SUPERNUS PHARMACEUTICALS has 68 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

68 patents

Patent portfolio

Page 1 of 2

  1. US 12121523

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11911368

    Method of treatment of CNS disorders

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11896599

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11638708

    Method of treatment of aggression

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11458143

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11351120

    Use of higher doses of modified release huperzine formulations

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11324753

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11166960

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11077114

    Stabilized formulations of CNS compounds

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10314790

    Sustained-release formulations of topiramate

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10265319

    Formulations of viloxazine

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10220042

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10201547

    Method of treatment of aggression

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10160733

    Methods for producing viloxazine salts and novel polymorphs thereof

    Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10149853

    Stabilized formulations of CNS compounds

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10058556

    Method of treatment of aggression

    Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10005743

    Methods for producing viloxazine salts and novel polymorphs thereof

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9855278

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9801887

    Method of treatment of aggression

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9744137

    Topiramate compositions and methods of enhancing its bioavailability

    Expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9662338

    Formulations of viloxazine

    Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9622983

    Sustained-release formulations of topiramate

    Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9603853

    Formulations of viloxazine

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9555004

    Sustained-release formulations of topiramate

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9549940

    Sustained-release formulations of topiramate

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9434703

    Viloxazine compositions

    Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9403783

    Methods for producing viloxazine salts and novel polymorphs thereof

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9393203

    Osmotic drug delivery system

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9370525

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9358204

    Formulations of viloxazine

    Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9351975

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9308176

    Less abusable pharmaceutical preparations

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9144551

    Drug formulations having reduced abuse potential

    Expires Mon Sep 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9119791

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9119792

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8992989

    Sustained-release formulations of topiramate

    Expires Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8906413

    Drug formulations having reduced abuse potential

    Expires Mon Dec 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8889191

    Sustained-release formulations of topiramate

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8877248

    Sustained-release formulations of topiramate

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8821930

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8808714

    Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics

    Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8748472

    Stabilized formulations of CNS compounds

    Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8747897

    Osmotic drug delivery system

    Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8709476

    Compositions of quaternary ammonium compounds containing bioavailability enhancers

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8709478

    Once daily formulations of tetracyclines

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8663683

    Sustained-release formulations of topiramate

    Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8617600

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8598191

    Controlled release compositions of gamma-hydroxybutyrate

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does SUPERNUS PHARMACEUTICALS have?

68 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do SUPERNUS PHARMACEUTICALS patents expire?

1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.